Galantos Pharma

Based in Mainz, Germany, Galantos Pharma develops pharmaceutical treatments and novel neuroprotective medications targeting neurodegenerative diseases, with a primary commercial focus on Alzheimer's dementia. The biotechnology company focuses on optimizing the approved natural compound galantamine and advancing its proprietary lead central nervous system compound, Memogain, into formal clinical trials. The privately held enterprise has successfully secured vital capital through multiple financing rounds, including a €4,400,000 Series C tranche, to support its ongoing preventive drug development programs. According to recent SEC filings, the growing firm has accumulated €10,000,000 in total investment, with structural provisions to increase funding up to €15,000,000 under the strategic guidance of Chief Business Officer Andreas Köpke. Galantos Pharma was founded in 2005 by Professor Alfred Maelicke following his establishment of the related Galantos Genetics laboratory at TZM Mainz during the previous year.